Lorlatinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 801 publications

Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.

Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.

Journal: Tumori

Published: June 04, 2026

Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non-Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT).

Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non-Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT).

Journal: JCO global oncology

Published: June 04, 2026

Establishment of pediatric neuroblastoma cell line and its resistance mechanism to lorlatinib

Establishment of pediatric neuroblastoma cell line and its resistance mechanism to lorlatinib

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: May 18, 2026

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy.

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy.

Journal: Journal of medical economics

Published: April 27, 2026

Neuropsychiatric adverse events associated with lorlatinib in ALK-positive NSCLC.

Neuropsychiatric adverse events associated with lorlatinib in ALK-positive NSCLC.

Journal: The International journal of risk & safety in medicine

Published: April 13, 2026

A Zinc Finger Protein-Based Prognostic Model in Lung Adenocarcinoma Identifies FGD3 as a Marker Associated with Lorlatinib Resistance.

A Zinc Finger Protein-Based Prognostic Model in Lung Adenocarcinoma Identifies FGD3 as a Marker Associated with Lorlatinib Resistance.

Journal: Cancers

Published: April 09, 2026

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.

Journal: Future oncology (London, England)

Published: April 08, 2026

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 07, 2026

Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.

Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.

Journal: Frontiers in oncology

Published: March 27, 2026

Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival.

Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival.

Journal: The oncologist

Published: March 26, 2026

Primary glioblastoma mimicking brain metastasis in ALK-positive lung adenocarcinoma: a case report and literature review.

Primary glioblastoma mimicking brain metastasis in ALK-positive lung adenocarcinoma: a case report and literature review.

Journal: Frontiers in oncology

Published: March 24, 2026

Lorlatinib protects dopaminergic neurons by inhibiting ALK-mediated neuroinflammation in a mouse model of Parkinson's disease.

Lorlatinib protects dopaminergic neurons by inhibiting ALK-mediated neuroinflammation in a mouse model of Parkinson's disease.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 19, 2026

Showing 1-12 of 801

Last Updated: 06/30/2026